GRAIL Stock (NASDAQ:GRAL)
Previous Close
$46.33
52W Range
$20.44 - $118.84
50D Avg
$86.20
200D Avg
$65.47
Market Cap
$1.73B
Avg Vol (3M)
$1.28M
Beta
5.21
Div Yield
-
GRAL Company Profile
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IDYA | IDEAYA Biosciences, Inc. |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| NVST | Envista Holdings Corp |
| RARE | Ultragenyx Pharmaceutical Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| XENE | Xenon Pharmaceuticals Inc. |
| DYN | Dyne Therapeutics, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| APGE | Apogee Therapeutics, Inc. |